**Title: QbTest Gains Endorsement from NICE for ADHD Diagnosis**
The QbTest, a diagnostic tool designed to assess Attention Deficit Hyperactivity Disorder (ADHD), has received a positive evaluation and recommendation from the National Institute for Health and Care Excellence (NICE) through its Diagnostic Assessment Programme. This endorsement marks a significant milestone for the test, highlighting its potential to enhance ADHD diagnosis and management.
Developed to objectively measure symptoms of ADHD, the QbTest combines attention and impulse control assessments with motion analysis. By offering quantifiable data, it aids clinicians in making more informed diagnostic and therapeutic decisions. The tool promises to improve accuracy in diagnosing ADHD, potentially reducing misdiagnosis, and tailoring more effective treatment plans.
NICE’s recommendation follows a rigorous evaluation process that considers clinical efficacy, cost-effectiveness, and the potential impact on patient outcomes. This positive assessment underscores the QbTest’s value in clinical practice and may facilitate its adoption within healthcare systems, providing a standardized approach to ADHD diagnosis.
For biotech investors, the endorsement by NICE could translate to increased market adoption and expansion opportunities for the QbTest, enhancing its commercial viability. With the rising prevalence of ADHD globally, this diagnostic tool is positioned to capture significant market interest.
For further details, visit [Business Wire](http://www.businesswire.com/portal/site/home/news/industry/?vnsId=31070).